Mirodenafil
Mirodenafil is an experimental drug belonging to a class of drugs called PDE5 inhibitors, which many other erectile dysfunction drugs such as sildenafil, tadalafil, and vardenafil also belong to. Like udenafil, lodenafil and avanafil it belongs to a new generation of PDE5 inhibitors.
It is not currently approved for use in the United States by the U.S. Food and Drug Administration, but clinical trials are being conducted.[1][2][3]
References
- ^ Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, Kim SW, Lee SW, Min KS, Moon KH, Park JK, Park K, Park NC, Suh JK, Yang DY, Jung HG (November 2008). "Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction". The Journal of Sexual Medicine 5 (11): 2672–80. doi:10.1111/j.1743-6109.2008.00945.x. PMID 18638004.
- ^ Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS (June 2009). "Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea". Clinical Therapeutics 31 (6): 1234–43. doi:10.1016/j.clinthera.2009.06.008. PMID 19695390.
- ^ Shin KH, Kim BH, Kim TE, Kim JW, Yi S, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS (December 2009). "The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study". Clinical Therapeutics 31 (12): 3009–20. doi:10.1016/j.clinthera.2009.12.012. PMID 20110038.